Gavi and the "Next" Pandemic Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

• COVAX Funding: Approximately $16 billion raised through the Gavi COVAX Advance Market Commitment (AMC) and self-financing participants.
• Routine Immunization Impact: Gavi has immunized over 1 billion children since 2000, preventing 17.3 million future deaths.
• Market Shaping: Gavi reduced the cost of the pentavalent vaccine by 67 percent between 2006 and 2020.
• Donor Commitment: The Gavi 5.0 cycle (2021-2025) required $8.8 billion in core funding, which was exceeded during the 2020 Global Vaccine Summit.
• Zero-Dose Children: Financial requirements have increased as the number of zero-dose children reached 14.3 million in 2022, a slight recovery from the pandemic peak but still above 2019 levels.

Operational Facts

• Delivery Volume: COVAX shipped nearly 2 billion doses to 146 countries by early 2023.
• Supply Chain Infrastructure: Gavi supports cold chain equipment in over 70 countries, including solar-powered refrigeration units.
• Regional Concentration: Less than 1 percent of vaccine manufacturing for Africa takes place on the continent.
• Lead Times: During the COVID-19 pandemic, high-income countries secured bilateral deals for 70 percent of initial global supply, delaying COVAX deliveries by 4 to 6 months.
• Product Portfolio: Gavi currently supports 19 infectious disease vaccines.

Stakeholder Positions

• Dr. Seth Berkley (Outgoing CEO): Emphasized that COVAX was a successful proof of concept but suffered from vaccine nationalism and lack of at-risk financing.
• Dr. Sania Nishtar (Incoming CEO): Inherits the challenge of Gavi 6.0, focusing on climate change and pandemic preparedness without diluting routine immunization.
• African Union/Africa CDC: Advocating for the New Public Health Order, targeting 60 percent local vaccine production by 2040.
• Pharmaceutical Manufacturers: Prefer bilateral contracts with high-income countries due to pricing transparency and immediate payment terms.
• Donor Nations: Expressing concern over donor fatigue and shifting priorities toward domestic economic recovery.

Information Gaps

• Detailed unit cost breakdown for the proposed African Vaccine Manufacturing Accelerator (AVMA).
• Specific retention rates for healthcare workers in Gavi-supported countries post-pandemic.
• Clear data on the exact volume of vaccine doses wasted due to short shelf lives and late-stage deliveries in 2021-2022.

2. Strategic Analysis

Core Strategic Question

• How can Gavi integrate permanent pandemic preparedness into its core mission without compromising the recovery of routine immunization programs?
• What structural changes are required to ensure equitable vaccine access during Day Zero of the next pandemic?

Structural Analysis

Porter's Five Forces Applied to Global Vaccine Markets:

• Supplier Power: High. A small number of multinational corporations control the intellectual property and manufacturing capacity for mRNA and viral vector platforms.
• Bargaining Power of Buyers: Fragmented. While Gavi aggregates demand for low-income countries, high-income countries act independently, outbidding the collective.
• Threat of Substitutes: Low. No viable alternative to vaccination exists for rapid pandemic suppression.
• Competitive Rivalry: Moderate. Competition exists for donor capital rather than market share in the low-income segment.

Strategic Options

Option 1: The Regionalization Pivot (AVMA Focused)

• Rationale: Shift from a centralized procurement model to a distributed manufacturing model by subsidizing the African Vaccine Manufacturing Accelerator.
• Trade-offs: Higher short-term costs and potential inefficiencies in exchange for long-term supply security.
• Resource Requirements: $1 billion initial capital injection and technical transfer agreements with patent holders.

Option 2: The Contingent Financing Model (Day Zero Fund)

• Rationale: Establish a pre-negotiated, at-risk fund that activates immediately upon a WHO pandemic declaration.
• Trade-offs: Requires donors to commit capital that may remain idle; high opportunity cost.
• Resource Requirements: Binding legal agreements and a $5 billion liquidity facility.

Preliminary Recommendation

Gavi should pursue Option 1, the Regionalization Pivot. The COVID-19 experience proved that centralized procurement cannot overcome vaccine nationalism. By diversifying manufacturing geography, Gavi changes the structural dynamics of supply. This approach aligns with the African Union goals and reduces the logistical burden of the cold chain over the long term.

3. Implementation Roadmap

Critical Path

• Month 1-3: Finalize the African Vaccine Manufacturing Accelerator (AVMA) financial structure and eligibility criteria for manufacturers.
• Month 4-9: Execute technology transfer agreements with at least two global vaccine manufacturers for priority platforms (mRNA or protein subunit).
• Month 10-18: Coordinate with national regulatory authorities in hub countries (e.g., Senegal, South Africa, Rwanda) to harmonize vaccine approval standards.
• Month 19-24: Launch the first procurement tender specifically reserved for African-produced vaccines to guarantee market demand.

Key Constraints

• Regulatory Maturity: Many target regions lack WHO-certified Level 3 or 4 regulatory bodies, which is a prerequisite for international vaccine distribution.
• Workforce Expertise: Specialized bioprocessing engineering talent is scarce in the regions targeted for manufacturing expansion.
• Donor Fatigue: Securing multi-year commitments for regional hubs is difficult when donor budgets are tightening.

Risk-Adjusted Implementation Strategy

The strategy assumes a phased roll-out. Rather than attempting full-scale production of 19 vaccines, the initial phase must focus on high-volume, high-predictability vaccines (e.g., Yellow Fever or Measles) to stabilize the manufacturing lines. This ensures the facilities remain operational and financially viable during inter-pandemic periods, providing the warm base capacity needed for a rapid pandemic pivot.

4. Executive Review and BLUF

BLUF

Gavi must transition from a procurement intermediary to a market architect. The central failure of COVAX was not financial; it was a structural dependence on a centralized supply chain that collapsed under nationalistic pressure. To survive the next pandemic, Gavi must operationalize the African Vaccine Manufacturing Accelerator (AVMA) immediately. This requires moving beyond simple donation-based models toward a system of guaranteed regional purchase agreements. Success depends on securing $1 billion in at-risk capital to de-risk local production. Failure to diversify manufacturing locations will result in a repeat of the 2020 inequity cycle.

Dangerous Assumption

The analysis assumes that regional manufacturing will naturally lead to equitable distribution. In reality, a sovereign nation hosting a manufacturing plant may still exercise export bans or seize local production during a crisis, regardless of Gavi financing. Physical proximity does not guarantee legal priority.

Unaddressed Risks

• Financial Sustainability: Regional plants may become white elephants if they cannot compete with the scale and pricing of Indian or Chinese manufacturers during non-pandemic years. Probability: High. Consequence: Severe.
• Pathogen Evolution: Future pandemics may require platforms (e.g., specialized therapeutics) that the currently planned vaccine hubs are not equipped to produce. Probability: Moderate. Consequence: Moderate.

Unconsidered Alternative

The team did not fully evaluate a Licensing and Intellectual Property (IP) Enforcement strategy. Instead of building new factories, Gavi could use its massive purchasing power to mandate open-licensing clauses in all future routine immunization contracts. This would force technology sharing as a condition of doing business with Gavi, bypassing the need for expensive new infrastructure subsidies.

VERDICT: APPROVED FOR LEADERSHIP REVIEW